Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH
Go back to Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH| (NASDAQ: MDGL) | Delayed: 513.43 +0.55 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $512.88 | 52 Week High | $18.24 | |||
| Open | $513.36 | 52 Week Low | $6.60 | |||
| Day High | $522.00 | P/E | N/A | |||
| Day Low | $507.57 | EPS | $0.00 | |||
| Volume | 266,384 | |||||
